BoffaDJ, RosenJE, MallinK, Using the National Cancer Database for outcomes research: a review. JAMA Oncol 2017;3:1722–1728.2824119810.1001/jamaoncol.2016.6905)| false
ZaorskyNG, ZhangY, WalterV, et al.Clinical trial accrual at initial course of therapy for cancer and its impact on survival. J Natl Compr Canc Netw2019;17:1309–1316.
ZaorskyNG, ZhangY, WalterV, Clinical trial accrual at initial course of therapy for cancer and its impact on survival. J Natl Compr Canc Netw 2019;17:1309–1316.3169398610.6004/jnccn.2019.7321)| false
HaslamA, PrasadV.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open2019;2:e192535.
HaslamA, PrasadV.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535.10.1001/jamanetworkopen.2019.253531050774)| false
MarquartJ, ChenEY, PrasadV.Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol2018;4:1093–1098.
MarquartJ, ChenEY, PrasadV.Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 2018;4:1093–1098.2971018010.1001/jamaoncol.2018.1660)| false
TchelebiL, BatchelderE, WangM, et al. Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies JNCI Cancer Spectrum 2021:pkab050.
TchelebiL, BatchelderE, WangM, Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies JNCI Cancer Spectrum 2021:pkab050.10.1093/jncics/pkab050)| false